Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Decitabine and FR901228 in Treating Patients With Relapsed or Refractory Leukemia, Myelodysplastic Syndromes, or Myeloproliferative Disorders

This study has been completed.
Information provided by (Responsible Party):
National Cancer Institute (NCI) Identifier:
First received: June 13, 2005
Last updated: February 8, 2013
Last verified: September 2006
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Estimated Study Completion Date: No date given
  Primary Completion Date: September 2006 (Final data collection date for primary outcome measure)